MicroRNAs (miRNAs) are involved in essential biological activities ([@bib4]; [@bib1]). Recent studies have revealed differential expression of miRNAs in various cancers, including oral cancer, suggesting that certain miRNAs play roles in tumourigenesis ([@bib2]; [@bib17]). In addition, previous studies have revealed that some miRNAs are closely associated with clinical outcomes ([@bib13]). Moreover, miRNA expression may predict the efficacy of therapies, including radiotherapy ([@bib11]). In fact, miRNAs have been shown to modulate the radiosensitivity of primary human dermal microvascular endothelial cells ([@bib15]), lung cancer cells ([@bib16]) and breast cancer cells ([@bib10]). However, irradiation-induced alterations in miRNA profiles have not been analysed in oral squamous cell carcinoma (OSCC). Thus, this study aimed to identify miRNAs associated with radioresistance in OSCC and reveal their biological function and clinical significance.

Materials and Methods
=====================

Analysis of predicted target genes
----------------------------------

To identify crucial miRNAs for *intercellular adhesion molecule-2* (*ICAM2*) expression, we examined miRNAs that had binding sites like *ICAM2* and had been reported to be related to human cancer, especially proliferation, radioresistance and chemoresistance, with publicly available algorithms (TargetScan (<http://www.targetscan.org/>), EMBL-EBI (<http://www.ebi.ac.uk/>) or microRNA.org (<http://www.microrna.org/microrna/>)).

Cell lines and tissue specimens
-------------------------------

The OSCC-derived cell lines used were HSC-2, HSC-3, HSC-4, SCC4, HO-1-N-1 and Ca9-22 (Human Science Research Resources Bank, Osaka, Japan). Five independent human normal oral keratinocyte (HNOK) cell lines were cultured and maintained in defined keratinocyte-serum-free medium (Life Technologies Corporation, Grand Island, NY, USA) ([@bib14]). Tissue samples from 50 unrelated Japanese patients with primary OSCC who were treated at Chiba University Hospital ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) were collected after obtaining informed consents under a protocol that was approved by the Chiba University institutional review board.

RNA extraction and reverse transcription
----------------------------------------

Total RNA was extracted with TRIzol Reagent (Life Technologies Corporation) according to the manufacturer\'s instructions. Complementary DNA (cDNA) was synthesised from total RNA using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare, Little Chalfont, UK), an oligo(dT) primer (Sigma-Aldrich Co. LLC, St Louis, MO, USA) for *ICAM2* and the NCode VILO miRNA cDNA Synthesis Kit (Life Technologies Corporation) for miRNA, according to the manufacturers\' protocols.

Real-time quantitative reverse transcriptase--PCR (qRT--PCR) analysis
---------------------------------------------------------------------

Real-time qRT*--*PCR was performed to validate miRNA and mRNA expression with the NCode EXPRESS SYBR GreenER microRNA qRT*--*PCR Kit (Life Technologies Corporation) for miRNA and a LightCycler FastStart DNA Master SYBR Green 1 Kit (Roche Diagnostics GmbH, Mannheim, Germany) for mRNA. Normalised expression was calculated with 18S ribosomal RNA for miRNA and glyceraldehyde-3-phosphate dehydrogenase for mRNA. Transcript amount was estimated from standard curves and normalised. The nucleotide sequences of the specific primers for miRNAs and *ICAM2* are shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Transfection with miR-125b
--------------------------

The HSC-2 and HSC-3 cells (2 × 10^5^) were transfected with mirVana miRNA mimic (microRNA-125b) and mirVana miRNA Mimic Negative Control \#1 (Life Technologies Corporation) at a final concentration of 50 nℳ. The cells were transfected with miRNA duplexes with Lipofectamine 2000 reagent (Life Technologies Corporation) by following the manufacturer\'s protocol. The pmax-green fluorescent protein (GFP) plasmid (Lonza Group Ltd, Basel, Switzerland) was co-transfected simultaneously, and the transfection efficiency was determined by analysing GFP-expressing cells with flow cytometry.

Construction of reporter plasmids and luciferase reporter assays
----------------------------------------------------------------

The full-length 3′-untranslated region (UTR) of *ICAM2* containing putative miR-125b-binding sites was subcloned into a pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega Corporation, Madison, WI, USA) located 3′ to the firefly luciferase translational stop codon. A mutant 3′-UTR of *ICAM2* with a mutated sequence (5′-...AACTCAGTGTGACTC***[ATCGATC]{.ul}***TTGAGGTCC...-3′) in the complementary site for the miR-125b seed region was generated with fusion PCR (mutated sequence is expressed as italic and underlined). For the luciferase reporter assay, HSC-2 cells (5 × 10^4^) were placed in 24-well plates and co-transfected with 0.2 *μ*g of pmirGLO-3′-UTR-WT (*ICAM2*-WT) or pmirGLO-3′-UTR-MUT (*ICAM2-*Mut) and miR-125b or negative control with Lipofectamine 2000 (Life Technologies Corporation). Assays were performed 24 h after transfection with the Dual-Luciferase Reporter Assay System (Promega Corporation). Transfections were done three times in independent experiments.

Cell proliferation assay
------------------------

Transfectant and parental cells were seeded in 12-well plates (1 × 10^4^ viable cells per well). Cells were harvested 1, 2, 3 and 4 days later, and the cells were trypsinised and counted with a haemocytometer in triplicate.

X-ray irradiation and clonogenic survival assay
-----------------------------------------------

Transfectant and parental cells were irradiated with four single-radiation doses (2, 4, 6 and 8 Gy) with X-ray-irradiation equipment (MBR-1520R-3; Hitachi, Tokyo, Japan) at a source-to-target distance of 55 cm when the cells reached 70--80% confluence ([@bib5]; [@bib8]). The colonies were stained with crystal violet (Sigma-Aldrich Co. LLC), and colonies of ⩾50 cells were counted ([@bib8]). Each experiment was repeated at least three times.

Statistical analysis
--------------------

Clinicopathological profiles were assessed by *χ*^2^ tests and Fisher\'s exact tests. Overall survival rate was investigated by Kaplan--Meier analyses, and the difference was analysed with log-rank tests. Student\'s *t*-tests were used for other analyses. All tests were two sided. *P*\<0.05 was considered significant.

Results
=======

Analysis of the predicted target gene
-------------------------------------

We initially performed predicted target gene analyses of *ICAM2* mRNA with publicly available algorithms to find miRNA that potentially regulated *ICAM2* expression. The databases showed that miR-125b had complementary sequences for *ICAM2* mRNA, suggesting that miR-125b could directly regulate *ICAM2* activity through imperfect base pairing with the *ICAM2* mRNA 3′-UTR ([Supplementary Figure 1A--C](#sup1){ref-type="supplementary-material"}). Altered miR-125b expression has been reported in various human cancers, and miR-125b-induced cell cycle arrest has been reported for several cancers ([@bib3]; [@bib6]; [@bib18]). We hypothesised that miR-125b plays a role in OSCC by regulating *ICAM2* expression. Thus, miR-125b was analysed further.

The miR-125b levels in OSCC-derived cell lines and OSCC samples
---------------------------------------------------------------

The expression of miR-125b was less than twice that of HNOK cells in all cell lines ([Figure 1A](#fig1){ref-type="fig"}). Lower expression levels were observed in 39 of 50 (78%) OSCC samples compared with matched normal tissues ([Figure 1B](#fig1){ref-type="fig"}). The median miR-125b expression level was 0.280 and 0.132 in normal tissues and OSCC samples, respectively ([Figure 1C](#fig1){ref-type="fig"}), which was significant (*P*=0.019; Student\'s *t*-test).

The relationship between clinical factors and miR-125b expression was evaluated ([Table 1](#tbl1){ref-type="table"}). The expression of miR-125b was significantly lower in advanced stages (III+IV) than in early stages (I+II) (*P*=0.037).

Prognostic significance of miR-125b expression in OSCC
------------------------------------------------------

Tumours with significant miR-125b downregulation (median \<0.34) were considered low miR-125b (*n*=25). Survival curves for miR-125b expression are shown in [Figure 1D](#fig1){ref-type="fig"}. Kaplan--Meier analyses indicated that miR-125b expression was significantly associated with overall survival (*P*=0.038; [Figure 1D](#fig1){ref-type="fig"}), suggesting that decreased miR-125b expression in patients with OSCCs was significantly associated with poor prognoses.

Effects of miR-125b overexpression on cellular proliferation and radiosensitivity
---------------------------------------------------------------------------------

After validating miR-125b overexpression ([Supplementary Figure 2A and B](#sup1){ref-type="supplementary-material"}) with appropriate transfection efficiency, miR-125b-transfected cells were subjected to functional assays. The proliferation rate was significantly lower in miR-125b-transfected HSC-2 and HSC-3 cells after 72 and 96 h compared with negative controls ([Figures 2A and B](#fig2){ref-type="fig"}). In HSC-2 and HSC-3 cells, the survival rates were significantly decreased in 6-Gy-irradiated and 8-Gy-irradiated miR-125b transfectants compared with negative controls ([Figures 2C and D](#fig2){ref-type="fig"}).

The miR-125b overexpression suppressed ICAM2 expression in OSCC-derived cell lines
----------------------------------------------------------------------------------

We examined whether altered radiosensitivity was associated with the ICAM2-related signalling pathway. The expression of *ICAM2* was downregulated in miR-125b-transfected OSCC cells ([Figure 2E and F](#fig2){ref-type="fig"}).

MiR-125b targets ICAM2
----------------------

The relative luciferase activity of the reporter gene containing wild-type *ICAM2* 3′-UTR was significantly suppressed when miR-125b was co-transfected. However, decreased luciferase activity was not observed in cells with the reporter gene containing mutated *ICAM2* 3′-UTR ([Figure 2G](#fig2){ref-type="fig"}). This suggested that the *ICAM2* 3′-UTR was a miR-125b target and that miR-125b suppressed *ICAM2* expression through binding.

Discussion
==========

We have previously identified genes, including *ICAM2*, that play important roles in OSCC radioresistance (HSC-2 and HSC-3) ([@bib9], [@bib8]). The *ICAM2* has been suggested to facilitate an apoptotic-blocking survival signal by activating the PI3K/AKT pathway ([@bib12]). Another study has reported that *ICAM2* expression deficiencies result in impaired angiogenesis *in vitro* and *in vivo*, defective *in vitro* migration and increased apoptosis ([@bib7]). The downregulation of *ICAM2* siRNA enhanced OSCC radiosensitivity and increased apoptosis through AKT phosphorylation and caspase-3 activation ([@bib8]). Moreover, *ICAM2* overexpression induced greater OSCC resistance to X-ray irradiation ([@bib9]).

In this study, decreased *ICAM2* expression was observed in both miR-125b-transfected HSC-2 and miR-125b-transfected HSC-3 cells; moreover, radiosensitivity towards X-ray irradiation was enhanced in miR-125b-transfected HSC-2 and HSC-3 cells. Luciferase reporter assays showed that the *ICAM2* 3′-UTR was a miR-125b target. Therefore, the data strongly suggest that miR-125b is associated with radiation response through regulating *ICAM2* expression in OSCC.

The importance of miR-125b as an anticancer agent was demonstrated by the impact of its expression on cell proliferation. We showed that OSSC-derived cells proliferated less rapidly when miR-125b expression was increased by transfection, suggesting that miR-125b could regulate cell proliferation. This finding may be associated with cell cycle regulation as miR-125b-induced cell cycle arrest has been reported for several cancers ([@bib3]; [@bib6]; [@bib18]).

In conclusion, controlling miR-125b expression or activity could contribute to suppressing cell proliferation and overcoming radioresistance in OSCC, which could be useful in developing a cure for OSCC. Moreover, miR-125b was significantly correlated with survival and radiotherapy response in OSCC and could be used as a prognostic marker.
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![**Expression profiles of miR-125b in oral squamous cell carcinoma (OSCC)-derived cell lines and OSCC samples.** The quantification of miR-125b expression levels in OSCC-derived cell lines (**A**) and OSCC samples (**B**) was performed by real-time qRT*--*PCR analyses. The data are expressed as means±s.d. Significantly lower miR-125b expression levels were detected in primary OSCCs compared with matched normal tissues (*P*=0.019, Student\'s *t*-test) (**C**). The data are expressed as means±s.d. The overall survival rate was investigated by Kaplan--Meier analysis (**D**). Lower miR-125b expression levels were significantly associated with poor outcome in patients with OSCC. The log-rank test revealed significant *P-*values (*P*=0.038).](bjc2013175f1){#fig1}

![**Effect of miR-125b overexpression on OSCC-derived cell lines.** A cellular proliferation assay was performed to investigate the effects of the overexpression of miR-125b on the OSCC-derived cell lines HSC-2 (**A**) and HSC-3 (**B**). \*Significant differences between transfectants and negative controls (NCs; *P*\<0.05, Student\'s *t*-test). The data are expressed as means±s.d. Cell survival after irradiation was examined with a clonogenic survival assay (**C** and **D**). After exposure to 2, 4, 6 and 8 Gy of X-ray irradiation, cells were seeded and cultured. The significance of the differences between transfectant and NC cells is indicated with asterisks (\*) (*P*\<0.05, Student\'s *t*-test). The data are expressed as means±s.d. The *ICAM2* mRNA expression in miR-125b-transfected cells and NC cells in HSC-2 (**E**) and HSC-3 (**F**) is shown. The expression levels of *ICAM2* mRNA were decreased after the introduction of miR-125b to both cell lines (*P*\<0.01, Student\'s *t*-test). The data are expressed as means±s.d. The luciferase activity of the reporter gene containing the wild-type 3′-UTR of the *ICAM2* gene (*ICAM2*-WT) or the mutated 3′-UTR of the *ICAM2* gene (*ICAM2-*Mut) was determined (**G**). The data are expressed as means±s.d. Relative luciferase activity was significantly suppressed in the cells with *ICAM2*-WT when miR-125b was co-transfected (*P*=0.001, Student\'s *t*-test).](bjc2013175f2){#fig2}

###### Correlation between miR-125b expression and clinicopathological profiles

                                                   **MicroRNA-125b expression**             
  ------------------------------------------ ---- ------------------------------ ---------- --------------------------------------
  **Tumour size (T)**                                                                       
  T1                                          5              1 (20%)              4 (80%)    *P*=0.086[a](#t1-fn1){ref-type="fn"}
  T2                                          14             5 (36%)              9 (64%)                      
  T3                                          10             8 (80%)              2 (20%)                      
  T4                                          21             11 (53%)             10 (47%)                     
  T1+T2                                       19             6 (32%)              13 (68%)   *P*=0.079[b](#t1-fn2){ref-type="fn"}
  T3+T4                                       31             19 (61%)             12(39%)                      
  **Regional lymph node metastasis (*N*)**                                                  
  Negative                                    33             16 (48%)             17 (52%)   *P=*0.765[a](#t1-fn1){ref-type="fn"}
  Positive                                    17             9 (53%)              8 (47%)                      
  **Stage classification**                                                                  
  I                                           5              1 (20%)              4 (80%)    *P*=0.100[a](#t1-fn1){ref-type="fn"}
  II                                          6              1 (17%)              5 (83%)                      
  III                                         7              5 (71%)              2 (29%)                      
  IV                                          32             18 (56%)             14 (44%)                     
  I+II                                        11             2 (18%)              9 (82%)    *P*=0.037[b](#t1-fn2){ref-type="fn"}
  III+V                                       39             23 (59%)             16 (41%)                     
  **Differentiation**                                                                       
  Well                                        28             13 (46%)             15 (54%)   *P=0.776*[b](#t1-fn2){ref-type="fn"}
  Moderate+poor                               22             12 (55%)             10 (45%)                     

The *χ*^2^ test.

Fisher\'s exact test.
